The Technical Analyst
Vivos Therapeutics, Inc. [VVOS]
Exchange: Nasdaq Global Select Sector: Healthcare Industry: Medical Devices
Vivos Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: SELL (auto-tracking)
2.16% $1.420
Last updated: 16 May 2022 @ 11:45 am
FIND ALL MARKETS
FIND ALL STOCKS LISTED @ NASDAQ Live Signal Oslo
Live Signal Nasdaq
Live Signal Crypto
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 32.68 mill |
| EPS: | -0.955 |
| P/E: | 0.000 |
| Earnings Date: | May 16, 2022 |
| SharesOutstanding: | 23.01 mill |
| Avg Daily Volume: | 0.129 mill |
| RATING 2022-05-13 |
|---|
| B |
| Neutral |
| RATINGDETAILS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Strong Sell | |
| DE: | Neutral | |
| P/E: | Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 2/20 | 3/20 | 4/20 | 2/21 | 3/21 | 4/21 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt | n/a |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$3.29 (131.87%) $1.873 |
| Date: 2022-05-16 |
| True Range Average |
|---|
|
+/- $0.235 ( +/- 16.91%) Range: 1.155 - 1.625 |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2022-02-25 | Amman Bradford K. | Buy | 50 000 | Stock Option (Right to Buy) |
| 2022-02-25 | Huntsman Ronald Kirk | Buy | 125 000 | Stock Option (Right to Buy) |
| 2021-09-21 | Huntsman Ronald Kirk | Buy | 5 000 | Common Stock |
| 2021-08-31 | Amman Bradford K. | Buy | 83 334 | Stock Option (Right to Buy) |
| 2021-08-31 | Amman Bradford K. | Buy | 16 667 | Stock Option (Right to Buy) |
| INSIDER POWER |
|---|
| 89.34 |
| Last 24 transactions |
| Buy: 1 047 502 | Sell: 0 |
Forecast:
13:23 - $1.445
Live Trading Signals (every 1 min)
Forecast
1: 11:53 - $1.421
Forecast 2: 12:43 - $1.393
Forecast 3: 13:23 - $1.445
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $1.420 (2.16% ) |
| Volume | 0.0639 mill |
| Avg. Vol. | 0.129 mill |
| % of Avg. Vol | 49.42 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VVOS
160 Signals | Accuracy: 13.13% | Accuracy Buy: 11.25% | Accuracy Sell: 15.00%
Avg return buy: -1.63 % | Avg return sell: 1.55 %
$1 invested is now $0.26 or -74.08% since 20-04-22
| Date | Signal | @ | Closed | % | May 16 - 11:24 | sell | $1.420 | N/A | Active |
|---|---|---|---|---|
| May 16 - 10:26 | buy | $1.420 | $1.380 @ May 16 - 10:32 | -2.82% |
| May 16 - 09:38 | sell | $1.400 | $1.420 @ May 16 - 10:24 | 1.43% |
| May 16 - 09:35 | buy | $1.470 | $1.400 @ May 16 - 09:37 | -4.76% |
| May 13 - 15:53 | sell | $1.390 | $1.470 @ May 16 - 09:34 | 5.74% |
| May 13 - 15:41 | buy | $1.430 | $1.390 @ May 13 - 15:52 | -2.79% |
| May 13 - 15:17 | sell | $1.396 | $1.430 @ May 13 - 15:40 | 2.44% |
| May 13 - 15:14 | buy | $1.400 | $1.396 @ May 13 - 15:16 | -0.29% |
| May 13 - 12:27 | sell | $1.460 | $1.400 @ May 13 - 15:14 | -4.11% |
| May 13 - 10:59 | buy | $1.430 | $1.410 @ May 13 - 11:03 | -1.40% |
VVOS
Latest Press Releases
2022-03-31 16:05:00 - Press Release
Vivos Therapeutics Reports Fourth Quarter And Full Year 2021 financial Results And Operational Update
Fourth quarter revenue increased 33% year-over-year while full year revenue increased 29%
2022-03-08 09:11:00 - Press Release
Fast Company Selects Vivos Therapeutics For 2022 “world's Most Innovative Companies” List
Pioneer in treating dentofacial abnormalities and / or mild-to-moderate obstructive sleep apnea ranks among top 10 most innovative medical device companies of the year pioneer in treating dentofacial abnormalities and / or mild-to-moderate obstructive sleep apnea ranks among top 10 most innovative medical device companies of the year
2022-01-27 07:30:00 - Press Release
Vivos Therapeutics Files For Us Patent On Proprietary New Clinical Protocols After Seeing Further Significant Improvement In Reduction Of Key Sleep Apnea Metric
Vivos' continuous clinical improvement program yields promising data in ahi score reductions for patients with obstructive sleep apnea vivos' continuous clinical improvement program yields promising data in ahi score reductions for patients with obstructive sleep apnea
2022-01-19 07:30:00 - Press Release
Vivos Therapeutics Announces 18x Increase In Sleep Apnea Diagnostic Testing By Vivos Dentists Using Sleepimage Technology
Vivos also announces improved pricing agreement with sleepimage
2021-12-14 07:30:00 - Press Release
Vivos Therapeutics' Mmrna Oral Appliance now Eligible For Medicare Reimbursement
Mmrna is the first and only appliance of its kind covered by medicare
Latest News
2022-03-31 21:39:06 - Seeking Alpha
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q4 2021 Results - Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q4 2021 Results - Earnings Call Transcript
2022-03-31 08:14:00 - GlobeNewsWire
Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call
Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET
2022-03-06 08:06:06 - Seeking Alpha
Vivos Therapeutics: First Take After The Broad Market Sell-Off
Vivos Therapeutics, Inc. markets a jaw repositioning device that has the potential to cure patients' mild-to-moderate obstructive sleep apnea.
2022-03-02 08:00:00 - GlobeNewsWire
Vivos Therapeutics to Participate in Upcoming Investor Conferences
HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc . (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology company focused on developing and commercializing a suite of innovative diagnostic and treatment modalities for patients with dentofacial abnormalities and/or mild to moderate obstructive sleep apnea (OSA) and snoring, today announced that Kirk Huntsman, Chief Executive Officer, will participate in the following upcoming conferences.
2022-01-21 14:30:00 - PennyStocks
These 3 Penny Stocks Exploded Today, Here's Why
Here are three penny stocks you should add to your watchlist The post These 3 Penny Stocks Exploded Today, Here's Why appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2022-01-19 15:13:18 - Pulse2
Vivos Therapeutics Stock (VVOS): Why The Price Substantially Went Up Today
The stock price of Vivos Therapeutics Inc (NASDAQ: VVOS) increased by over 35% during intraday trading today. This is why it happened.
2022-01-19 11:44:53 - Benzinga
Why Are Vivos Therapeutics Shares Surging Today?
Vivos Therapeutics Inc (NASDAQ:VVOS) announced significant increases across several key metrics for its SleepImage Home Sleep Apnea Tests (HST). In particular, for the quarter ended December 31, 2021, versus the three months ended December 31, 2020, Vivos reported an 18 times increase in the total number of HSTs given across the network of Vivos trained dentists (known as Vivos Integrated Practices or VIPs).
2022-01-19 09:15:43 - PennyStocks
4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps
Small cap stocks to watch after Trump bump hits penny stocks The post 4 Penny Stocks To Watch After DWAC Stock Wakes Up Small Caps appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
2021-11-15 21:11:07 - Seeking Alpha
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q3 2021 Results - Earnings Call Transcript
Vivos Therapeutics, Inc. (VVOS) CEO Kirk Huntsman on Q3 2021 Results - Earnings Call Transcript
2021-10-19 11:30:00 - PRNewsWire
Vivos Therapeutics and Candid Announce Strategic Collaboration to Deliver A Comprehensive Sleep Apnea and Orthodontic Treatment Solution
HIGHLANDS RANCH, Colo., Oct. 19, 2021 /PRNewswire/ -- Vivos Therapeutics, Inc. ("Vivos" or "the Company") (NASDAQ: VVOS), a medical technology company focused on developing and commercializing innovative diagnostic and treatment modalities for patients suffering from mild to moderate obstructive sleep apnea (OSA) and snoring, and Candid Care Co. ("Candid") , a digital platform for oral healthcare, today announced a new collaboration that will seek to provide patients with a comprehensive, whole-mouth solution to diagnose and treat OSA in adult patients and provide orthodontic treatment from the same provider network.